Abbott Laboratories (ABT) stock
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3034% above fair value
$104.48−0.23 (-0.22%)
Close on Nov 18, 2026Market cap $180.79BP/E 33.6Yield 2.30%
Abbott Laboratories operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Abbott Laboratories's operating income for the twelve months ending Jun 30, 2026 was $7.35B, down 2.2% year over year. For fiscal 2025 it was $8.05B, up 18.0% from the year before. Over ten years it grew 10.9% a year on average. The highest annual figure on record is $8.43B in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.05B | +18.0% |
| FY2024 | Dec 31, 2024 | $6.83B | +5.4% |
| FY2023 | Dec 31, 2023 | $6.48B | -22.5% |
| FY2022 | Dec 31, 2022 | $8.36B | -0.7% |
| FY2021 | Dec 31, 2021 | $8.43B | +57.3% |
| FY2020 | Dec 31, 2020 | $5.36B | +18.2% |
| FY2019 | Dec 31, 2019 | $4.53B | +24.2% |
| FY2018 | Dec 31, 2018 | $3.65B | +133.4% |
| FY2017 | Dec 31, 2017 | $1.56B | -48.3% |
| FY2016 | Dec 31, 2016 | $3.03B | +5.5% |
| FY2015 | Dec 31, 2015 | $2.87B | +10.3% |
| FY2014 | Dec 31, 2014 | $2.60B | +21.8% |
| FY2013 | Dec 31, 2013 | $2.13B | +56.8% |
| FY2012 | Dec 31, 2012 | $1.36B | -16.5% |
| FY2011 | Dec 31, 2011 | $1.63B | -73.2% |
| FY2010 | Dec 31, 2010 | $6.09B | -2.4% |
| FY2009 | Dec 31, 2009 | $6.24B | +9.5% |
| FY2008 | Dec 31, 2008 | $5.69B | +24.4% |
| FY2007 | Dec 31, 2007 | $4.58B | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.69B | -17.5% |
| Q1 FY2026 | Mar 31, 2026 | $1.35B | -20.6% |
| Q4 FY2025 | Dec 31, 2025 | $2.25B | +17.8% |
| Q3 FY2025 | Sep 30, 2025 | $2.06B | +10.7% |
| Q2 FY2025 | Jun 30, 2025 | $2.05B | +22.9% |
| Q1 FY2025 | Mar 31, 2025 | $1.69B | +22.2% |
| Q4 FY2024 | Dec 31, 2024 | $1.91B | +7.4% |
| Q3 FY2024 | Sep 30, 2024 | $1.86B | +12.9% |
| Q2 FY2024 | Jun 30, 2024 | $1.67B | +8.2% |
| Q1 FY2024 | Mar 31, 2024 | $1.39B | -8.2% |
| Q4 FY2023 | Dec 31, 2023 | $1.78B | +36.5% |
| Q3 FY2023 | Sep 30, 2023 | $1.65B | -6.9% |
| Q2 FY2023 | Jun 30, 2023 | $1.54B | -35.1% |
| Q1 FY2023 | Mar 31, 2023 | $1.51B | -48.2% |
| Q4 FY2022 | Dec 31, 2022 | $1.30B | -45.2% |
| Q3 FY2022 | Sep 30, 2022 | $1.77B | -30.5% |
| Q2 FY2022 | Jun 30, 2022 | $2.38B | +70.7% |
| Q1 FY2022 | Mar 31, 2022 | $2.91B | +38.1% |
| Q4 FY2021 | Dec 31, 2021 | $2.38B | -2.2% |
| Q3 FY2021 | Sep 30, 2021 | $2.55B | +70.3% |
| Q2 FY2021 | Jun 30, 2021 | $1.39B | +107.1% |
| Q1 FY2021 | Mar 31, 2021 | $2.11B | +178.2% |
| Q4 FY2020 | Dec 31, 2020 | $2.43B | +75.1% |
| Q3 FY2020 | Sep 30, 2020 | $1.50B | +24.8% |
| Q2 FY2020 | Jun 30, 2020 | $672.00M | -44.3% |
| Q1 FY2020 | Mar 31, 2020 | $758.00M | +2.6% |
| Q4 FY2019 | Dec 31, 2019 | $1.39B | +19.2% |
| Q3 FY2019 | Sep 30, 2019 | $1.20B | +20.4% |
| Q2 FY2019 | Jun 30, 2019 | $1.21B | +36.7% |
| Q1 FY2019 | Mar 31, 2019 | $739.00M | +21.5% |
| Q4 FY2018 | Dec 31, 2018 | $1.17B | +79.0% |
| Q3 FY2018 | Sep 30, 2018 | $995.00M | +29.4% |
| Q2 FY2018 | Jun 30, 2018 | $882.00M | +128.5% |
| Q1 FY2018 | Mar 31, 2018 | $608.00M | – |
| Q4 FY2017 | Dec 31, 2017 | $651.00M | -17.5% |
| Q3 FY2017 | Sep 30, 2017 | $769.00M | -14.3% |
| Q2 FY2017 | Jun 30, 2017 | $386.00M | – |
| Q1 FY2017 | Mar 31, 2017 | -$242.00M | – |
| Q4 FY2016 | Dec 31, 2016 | $789.00M | – |
| Q3 FY2016 | Sep 30, 2016 | $897.00M | – |
See a number that looks wrong?